Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent LitigationPRNewsWire • 12/11/20
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated MyelofibrosisBusiness Wire • 12/11/20
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with CiplaBusiness Wire • 12/11/20
5 Dividend-Paying Pharmaceutical Stocks to Buy for Solid 2021 Total Return24/7 Wall Street • 12/10/20
Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?Investors Business Daily • 12/09/20
Pentwater Solicits Holders of Bristol-Myers Squibb Contingent Value Rights to Provide Consent to Replace TrusteeBusiness Wire • 12/09/20
Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in ChemistryBusiness Wire • 12/08/20
Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First RemissionBusiness Wire • 12/07/20
Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020Business Wire • 12/07/20
Bristol Myers (BMY) Down 2.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/05/20
Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020Business Wire • 12/05/20